Wall Street analysts expect Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) to announce earnings of ($1.26) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Eiger BioPharmaceuticals’ earnings. The lowest EPS estimate is ($1.39) and the highest is ($1.04). Eiger BioPharmaceuticals reported earnings per share of ($1.49) during the same quarter last year, which would suggest a positive year-over-year growth rate of 15.4%. The company is expected to issue its next earnings results on Tuesday, November 14th.

According to Zacks, analysts expect that Eiger BioPharmaceuticals will report full-year earnings of ($5.41) per share for the current financial year, with EPS estimates ranging from ($5.52) to ($5.22). For the next financial year, analysts expect that the company will post earnings of ($5.16) per share, with EPS estimates ranging from ($5.86) to ($4.78). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that cover Eiger BioPharmaceuticals.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last issued its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($1.33) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.28) by ($0.05).

A number of equities analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Eiger BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a research note on Tuesday, June 6th. Oppenheimer Holdings, Inc. set a $34.00 target price on shares of Eiger BioPharmaceuticals and gave the company a “buy” rating in a research report on Thursday, June 8th. Wedbush reiterated an “outperform” rating and set a $34.00 target price (up from $28.00) on shares of Eiger BioPharmaceuticals in a research report on Wednesday, June 21st. BTIG Research initiated coverage on shares of Eiger BioPharmaceuticals in a research note on Friday, July 14th. They issued a “buy” rating and a $32.00 target price on the stock. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $36.00 target price on shares of Eiger BioPharmaceuticals in a research note on Tuesday, August 15th. Two research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. Eiger BioPharmaceuticals presently has an average rating of “Hold” and a consensus target price of $28.46.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/04/zacks-brokerages-anticipate-eiger-biopharmaceuticals-inc-eigr-will-announce-earnings-of-1-26-per-share.html.

Eiger BioPharmaceuticals (EIGR) traded up 4.35% during midday trading on Wednesday, hitting $12.00. The company had a trading volume of 85,062 shares. The company’s 50 day moving average is $9.71 and its 200-day moving average is $8.56. The company’s market cap is $100.40 million. Eiger BioPharmaceuticals has a one year low of $6.10 and a one year high of $14.75.

In other news, Director Jeffrey S. Glenn bought 15,000 shares of Eiger BioPharmaceuticals stock in a transaction dated Friday, September 1st. The shares were bought at an average price of $9.53 per share, for a total transaction of $142,950.00. Following the purchase, the director now owns 31,355 shares of the company’s stock, valued at $298,813.15. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 28.80% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of EIGR. Hikari Power Ltd boosted its holdings in shares of Eiger BioPharmaceuticals by 491.0% in the 2nd quarter. Hikari Power Ltd now owns 60,992 shares of the biotechnology company’s stock worth $482,000 after acquiring an additional 50,672 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in Eiger BioPharmaceuticals during the 2nd quarter worth approximately $272,000. LMR Partners LLP bought a new stake in Eiger BioPharmaceuticals during the 2nd quarter worth approximately $116,000. Bank of New York Mellon Corp grew its position in Eiger BioPharmaceuticals by 6.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 14,567 shares of the biotechnology company’s stock worth $115,000 after acquiring an additional 871 shares during the last quarter. Finally, Susquehanna International Group LLP bought a new stake in Eiger BioPharmaceuticals during the 2nd quarter worth approximately $114,000. Institutional investors own 59.94% of the company’s stock.

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Get a free copy of the Zacks research report on Eiger BioPharmaceuticals (EIGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.